Coloplast AS Class B
COLO B: XCSE (DNK)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
DKK 473.00 | Bsdl | Xclxyfjknl |
Coloplast: Stays a Step Ahead of Competition Thanks to Innovative New Products
Though inflationary pressures have been alleviated to some extent, Coloplast’s ongoing launches of key new products should damp operating margin until fiscal 2026. After taking another look at how these product introductions are going, we’re leaving our fair value estimate intact. Despite the incremental investment needed to support the commercialization of these new products, we think Coloplast’s advances in ostomy, continence care, and advanced wound technologies reinforce the foundation of the firm’s wide economic moat.